Oxidized-LDL levels are changed during short-term serum glucose variations and lowered with statin treatment in early Type 2 diabetes: a study of endothelial function and microalbuminuria
| Autor: | Francisco Pérez-Jiménez, Pablo Perez-Martinez, Jose Lopez-Miranda, R.A. Fernández de la Puebla, J M Vida, Carmen Marin, F. Fuentes, J.A. Paniagua |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Adult
Blood Glucose Male medicine.medical_specialty Statin medicine.drug_class Pyridines Endocrinology Diabetes and Metabolism Type 2 diabetes Placebo Excretion Endocrinology Double-Blind Method Diabetes mellitus Internal medicine Internal Medicine medicine Albuminuria Humans Aged Proteinuria business.industry Cerivastatin Middle Aged medicine.disease Lipoproteins LDL Vasodilation Diabetes Mellitus Type 2 Microalbuminuria Female Endothelium Vascular medicine.symptom Hydroxymethylglutaryl-CoA Reductase Inhibitors business medicine.drug |
| Zdroj: | Diabetic medicine : a journal of the British Diabetic Association. 22(12) |
| ISSN: | 0742-3071 |
| Popis: | Aims To investigate the role of HMG-CoA reductase inhibitor (statin) treatment during serum glucose variations on plasma oxidized LDL (ox-LDL) levels in obese patients with early Type 2 diabetes mellitus (T2D) and its relationship to endothelial biomarkers. Methods In a double-blind, randomized crossover study, 15 obese diet-treated T2D patients received cerivastatin (0.4 mg/day) or placebo for 3 months. Circulating ox-LDL levels were measured fasting and during a euglycaemic–hyperinsulinaemic clamp (∼5.5 mmol/l; EHC) and a hyperglycemic clamp (∼20 mmol/l; HC). An endothelium-dependent flow-mediated dilation (FMD) study was carried out and urinary albumin excretion (UAE) was measured at rest and during EHC. S-ICAM, s-VCAM and basal prothrombotic factors were also measured. Results During cerivastatin treatment, basal circulating ox-LDL levels decreased by 48% (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text